TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - August 04, 2016) - VAXIL BIO (TSX VENTURE: VXL),a biotechnology company specializing in immunotherapy, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent providing broad coverage over Vaxil's immunotherapy platform and its lead product, Orphan Drug Designated Immucin™.
This will become the first US Patent issued to Vaxil since the Company began developing its immunotherapies 10 years ago. ImMucin™ is an immunotherapy intended to train a patient's immune system, particularly T-cells and antibodies, to attack cancer cells via a specific domain, called the signal peptide, of the tumor marker MUC1. This domain bears significant advantages as an immunotherapeutic modality including its presence on approximately 90% of all cancer types. The notice indicates the patentability of claims covering the ImMucin™ peptide as well as claims reciting methods for treating or inhibiting cancer using the ImMucin™ peptide.
This is a highly important addition to Vaxil's existing patent portfolio and strengthens the Company's ability to protect its proprietary technologies as it continues rigorous testing and advancement of ImMucin™. Moreover, it positions Vaxil as the only player able to use the 21-mer peptide known as ImMucin™ for all MUC1 positive tumors. Immucin™ is the first product generated from Vaxil's proprietary VaxHit™ platform, and has been awarded Orphan Drug Status from the FDA and EMA. Vaxil believes there is potential for VaxHit™ to generate additional immunotherapy products targeting the signal peptide domains of other prominent tumor markers.
Read more: http://www.marketwired.com/press-release/vaxil-announces-key-us-patent-trademark-office-notice-allowance-its-immunotherapy-tsx-venture-vxl-2148040.htm